MX2022001133A - Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). - Google Patents

Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).

Info

Publication number
MX2022001133A
MX2022001133A MX2022001133A MX2022001133A MX2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A MX 2022001133 A MX2022001133 A MX 2022001133A
Authority
MX
Mexico
Prior art keywords
dosing regimen
ido inhibitor
antibody
epacadostat
binds
Prior art date
Application number
MX2022001133A
Other languages
English (en)
Inventor
Michael Smith
Robert C Newton
Sherry Owens
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2022001133A publication Critical patent/MX2022001133A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se relaciona con regímenes de dosificación para el tratamiento del cáncer mediante la administración de epacadostat en combinación con un anticuerpo, o un fragmento de anticuerpo del mismo, que se une a la PD-1.
MX2022001133A 2019-08-01 2020-07-31 Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). MX2022001133A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962881518P 2019-08-01 2019-08-01
PCT/US2020/044533 WO2021022172A1 (en) 2019-08-01 2020-07-31 A dosing regimen for an ido inhibitor

Publications (1)

Publication Number Publication Date
MX2022001133A true MX2022001133A (es) 2022-04-25

Family

ID=72139706

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001133A MX2022001133A (es) 2019-08-01 2020-07-31 Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).

Country Status (10)

Country Link
US (1) US20210030869A1 (es)
EP (1) EP4007602A1 (es)
JP (1) JP2022543062A (es)
KR (1) KR20220044527A (es)
CN (1) CN114502196A (es)
AU (1) AU2020319875A1 (es)
CA (1) CA3148776A1 (es)
IL (1) IL290006A (es)
MX (1) MX2022001133A (es)
WO (1) WO2021022172A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20217221B (en) 2005-05-10 2021-02-10 Incyte Holdings Corp Us Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CN104042611B (zh) 2008-07-08 2019-05-14 因塞特控股公司 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑
US20220010028A1 (en) * 2020-07-09 2022-01-13 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Compositions and methods for treating fibroids
US20230025464A1 (en) * 2021-07-09 2023-01-26 Macrogenics, Inc. Pharmaceutical compositions of a pd-1 antibody and use of the same
CA3223690A1 (en) * 2021-08-13 2023-02-16 Christopher CAROSINO Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP4456365B2 (ja) 2001-09-19 2010-04-28 アベンティス・ファーマ・ソシエテ・アノニム 化合物
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
SI1470124T1 (sl) 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20050008625A1 (en) 2003-02-13 2005-01-13 Kalobios, Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4667383B2 (ja) 2003-06-13 2011-04-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド アグリコシル抗ｃｄ１５４（ｃｄ４０リガンド）抗体およびその使用
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CN104042611B (zh) 2008-07-08 2019-05-14 因塞特控股公司 作为吲哚胺2，3-双加氧酶的抑制剂的1，2，5-噁二唑
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EP3381920B1 (en) 2010-10-25 2019-03-27 G1 Therapeutics, Inc. Cdk inhibitors
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
TWI696618B (zh) 2013-11-08 2020-06-21 美商英塞特控股公司 用於合成吲哚胺2,3-雙加氧酶抑制劑之方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
WO2017079669A1 (en) * 2015-11-04 2017-05-11 Incyte Corporation Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
AU2017278325A1 (en) * 2016-06-07 2019-01-24 Macrogenics, Inc. Combination therapy
WO2019136157A2 (en) * 2018-01-05 2019-07-11 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and ido expression to potentiate immunotherapy

Also Published As

Publication number Publication date
CA3148776A1 (en) 2021-02-04
JP2022543062A (ja) 2022-10-07
US20210030869A1 (en) 2021-02-04
CN114502196A (zh) 2022-05-13
WO2021022172A1 (en) 2021-02-04
AU2020319875A1 (en) 2022-02-17
IL290006A (en) 2022-03-01
KR20220044527A (ko) 2022-04-08
EP4007602A1 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
PH12020500075A1 (en) Checkpoint inhibitor bispecific antibodies
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
PH12020551705A1 (en) Compositions and methods for treating anemia
MX2019003338A (es) Tratamiento de cefalea en racimos.
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
MX2020006668A (es) Anticuerpos para lilrb2.
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
NZ738979A (en) Pd-1 antibodies
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
MY192705A (en) Compositions and methods for treating anemia
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
MX2019002728A (es) Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2018014863A (es) Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3.
MX2018008008A (es) Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
ZA202206993B (en) Anti-lilrb1 antibody and uses thereof
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.
MX2021000797A (es) Anticuerpos agonistas de cd226.
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2020009863A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.